Genetic Analysis presents ulcerative colitis risk test at UEG Week

For bladder cancer patients, the hardest part of treatment is often not knowing whether it will work. At Karolinska Institutet and SciLifeLab, researchers are developing tools that read a tumor's own molecular signals to predict who will benefit from novel systemic therapies – before treatment even begins.

The World Health Organization (WHO) has identified SynAct Pharma's resomelagon as one of six dengue drug candidates with evidence supporting further clinical development, according to a review published in The Lancet Microbe.

A Swedish healthcare delegation traveled to Kyiv on September 2–4 to strengthen cooperation on rebuilding Ukraine's healthcare system, timed to one of the most difficult periods for the city in months.

The ongoing struggle in the Nordic countries to keep prescription drug prices affordable without shutting out innovative, more expensive therapies continues to frustrate pharmaceutical companies as the introduction of new drugs to the region slows.

In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).

Once limited to decongestants, nasal drug delivery is emerging as one of medicine’s most promising frontiers, offering faster uptake, stronger immunity, and the potential to block transmission before disease takes hold.